Sugi Predict

Sugi Predict / Compounds / SCHEMBL8065362

SCHEMBL8065362

SCHEMBL8065362

CC(C)[C@H](NCc1ccccc1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.62
▸ MEP1B Q16820 2/20 0.52
▸ SIGMAR1 Q99720 1/20 0.52
▸ ITGB3 P05106 1/20 0.51
▸ ITGB1 P05556 1/20 0.51
▸ ITGAV P06756 1/20 0.51
▸ ITGA5 P08648 1/20 0.51
▸ HCRTR2 O43614 1/20 0.50
▸ MAPK1 P28482 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ GAA P10253 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ TRPM8 Q7Z2W7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8349459 1.00 ALDH1A1 (0.62) ALDH1A1MEP1BSIGMAR1ITGB3ITGB1
SCHEMBL29060375 1.00 ALDH1A1 (0.62) ALDH1A1MEP1BSIGMAR1ITGB3ITGB1
Hydrochloric Acid SCHEMBL28019583 0.98 ALDH1A1 (0.60) ALDH1A1MEP1BSIGMAR1ITGB3ITGB1
SCHEMBL27719676 0.91 ALDH1A1 (0.54) ALDH1A1MEP1BSIGMAR1ITGB3ITGB1
SCHEMBL8161047 0.90 ADAMTS4 (0.54) ALDH1A1ITGB3ITGB1ITGAVITGA5
SCHEMBL8093317 0.89 ALDH1A1 (0.54) ALDH1A1MEP1BSIGMAR1ITGB3ITGB1
SCHEMBL5087907 0.88 ALDH1A1 (0.51) ALDH1A1SIGMAR1TSHRKMT2AMEN1
SCHEMBL5085491 0.88 ALDH1A1 (0.51) ALDH1A1SIGMAR1TSHRKMT2AMEN1
SCHEMBL27853244 0.88 ALDH1A1 (0.51) ALDH1A1SIGMAR1TSHRKMT2AMEN1
SCHEMBL7876545 0.87 ALDH1A1 (0.53) ALDH1A1SIGMAR1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114778655-B Analysis method of amino acid derivative enantiomer structure based on natamycin 宁波大学 2025-03-04 — — CN disclosed
US-20240076282-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LIMITED (GB) 2024-03-07 — — US disclosed
US-11753398-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2023-09-12 — — US disclosed
CN-114778655-A Analytical method of natamycin based enantiomer structure of amino acid derivative 宁波大学 2022-07-22 — — CN disclosed
CN-111848727-B Preparation, activity and application of theanyl tetrahydroimidazopyridine-6-formyl nonpolar amino acid 首都医科大学 2022-04-22 — — CN disclosed
US-20210395227-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LIMITED (GB) 2021-12-23 — — US disclosed
US-11130746-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2021-09-28 — — US disclosed
CN-107698660-B imidazopyridine-6-formyl-Lys (Lys) -oligopeptides, their synthesis, activity and uses 首都医科大学 2021-06-08 — — CN disclosed
CN-108779098-B Therapeutic compounds 希四克斯探索有限公司 2021-04-09 — — CN disclosed
US-20200255404-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LIMITED (GB) 2020-08-13 — — US disclosed
CN-106366033-B A kind of double type structure supermolecular gel factor and preparation method thereof 南京理工大学 2019-05-07 — — CN disclosed
US-20190040041-A1 THERAPEUTIC COMPOUNDS INDIVIOR UK LIMITED (GB) 2019-02-07 — — US disclosed
EP-3408265-A1 THERAPEUTIC COMPOUNDS C4x Discovery Limited (GB) 2018-12-05 — — EP disclosed
WO-2017129829-A1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LIMITED (GB) 2017-08-03 — — WO disclosed
CN-106366033-A Supramolecular gelator of gemini type structure and preparation method of supramolecular gelator 南京理工大学 2017-02-01 — — CN disclosed
EP-0853612-B1 ALPHA-HYDRAZINO ACID DERIVATIVES AND METHOD FOR MAKING SAME CENTRE NAT RECH SCIENT (FR) 2000-06-14 — — EP disclosed
US-5962722-A α-hydrazino acid derivatives and method for making same CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1999-10-05 — — US disclosed
WO-1999010365-A2 5',5'-LINKED OLIGOMERS HAVING ANTI-THROMBIN ACTIVITY GILEAD SCIENCES, INC. (US) 1999-03-04 — — WO disclosed
EP-0853612-A1 ALPHA-HYDRAZINO ACID DERIVATIVES AND METHOD FOR MAKING SAME CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1998-07-22 — — EP disclosed
WO-1997009303-A1 ALPHA-HYDRAZINO ACID DERIVATIVES AND METHOD FOR MAKING SAME CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1997-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753398-B2 Therapeutic compounds HCRTR2, HCRTR1, NPY1R ALDH1A1 1070/4885MEP1B 3194/4885SIGMAR1 302/4885
US-20190040041-A1 THERAPEUTIC COMPOUNDS HCRTR2, HCRTR1, NPY1R ALDH1A1 1070/4885MEP1B 3194/4885SIGMAR1 302/4885
US-11130746-B2 Therapeutic compounds HCRTR2, HCRTR1, NPY1R ALDH1A1 1070/4885MEP1B 3194/4885SIGMAR1 302/4885
US-20240076282-A1 THERAPEUTIC COMPOUNDS HCRTR2, HCRTR1, NPY1R ALDH1A1 1070/4885MEP1B 3194/4885SIGMAR1 302/4885
US-20200255404-A1 THERAPEUTIC COMPOUNDS HCRTR2, HCRTR1, NPY1R ALDH1A1 1070/4885MEP1B 3194/4885SIGMAR1 302/4885
US-20210395227-A1 THERAPEUTIC COMPOUNDS HCRTR2, HCRTR1, NPY1R ALDH1A1 1070/4885MEP1B 3194/4885SIGMAR1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.